ANNOVIS BIO INC. COMMON STOCK

Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

06 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

24 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

16 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team

09 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap

02 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap

27 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

26 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data

25 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024

18 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

11 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Announces New Publication in a Peer-Reviewed Journal

21 May 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results

13 May 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders

06 May 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease

29 Apr 2024 10:10:00 By Nasdaq GlobeNewswire

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

02 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans

01 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease

20 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

27 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease

14 Feb 2024 07:30:00 By Nasdaq GlobeNewswire